Journal
HEPATOLOGY
Volume 65, Issue 2, Pages 745-748Publisher
WILEY
DOI: 10.1002/hep.28692
Keywords
-
Categories
Funding
- National Institute of Diabetes and Digestive and Kidney Diseases
- National Institutes of Health (University of Michigan, Ann Arbor) [U01DK065184]
- Intramural Division
- National Cancer Institute
- National Institutes of Health
Ask authors/readers for more resources
Vemurafenib (Zelboraf; Genentech, CA) is a highly effective oral chemotherapy agent for patients with metastatic melanoma who carry the BRAF V600E mutation. Side effects of this protein kinase inhibitor (PKI) include arthralgia, rash, and fatigue, which are reported in up to one third of treated patients. Mild abnormalities in liver biochemistries were reported with vemurafenib use in 30% of subjects, 11% developed severe laboratory abnormalities, and acute liver failure has been reported (Table 1). Herein, a case of severe vemurafenib-induced granulomatous hepatitis leading to chronic cholestasis is reported along with a review of the hepatotoxicity of other PKIs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available